Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases — ZOSTER  

Vertebral Metastasis Clinical Trial

Official title: Phase III Randomized, Controlled, Open, Multicentre Medical-economic Study Evaluating the Efficacy of Adding ZOlédronique Acid to STERéotaxique Radiotherapy in the Treatment of Vertebral Metastases

Status Recruiting

Clinical Trial Summary

Hypo-fractured radiotherapy in stereotactic conditions (RSHF) of bone metastases allows high doses to be delivered to the affected bone segment while sparing adjacent healthy tissues as well as possible. In addition, it not only reduces pain and prevents spinal cord compression, but also improves long-term control of metastatic disease.

Zoledronic acid reduces bone complications. The economic literature shows that stereotactic radiotherapy, like zoledronic acid, are cost-effective strategies in these indications. The objective of this research project is to evaluate the efficiency of adding zoledronic acid to stereotactic radiotherapy in the treatment of vertebral metastases.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Neoplasm Metastasis
• Vertebral Metastasis

• NCT number: NCT03951493
• Study type: Interventional
• Source: Institut Cancerologie de l'Ouest
• Contact: Stéphane SUPIOT, MD
• Phone: +33240679900
• Email: stephane.supiot@ico.unicancer.fr
• Status: Recruiting
• Phase: Phase 3
• Start date: June 23, 2020
• Completion date: November 1, 2023